Comparison
3 Methylglutaconic Aciduria Type 9 C4540171 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria Type 9 and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 9 C4540171
A genetic disorder that affects brain development and motor function. It usually presents in early childhood with movement abnormalities and cognitive impacts. Care is supportive and focuses on managing individual symptoms.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 9 C4540171
0-5
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 9 C4540171
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 9 C4540171
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 9 C4540171
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 9 C4540171
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 9 C4540171
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-9-C4540171 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 9 C4540171 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Neurodevelopment | Early-childhood movement abnormalities and cognitive impact are described. | Developmental delay and learning challenges are often described. | Moderate |
| Metabolic clue | An organic-acid pattern may be investigated; no cutoff is supplied. | No defining metabolic abnormality is established here. | High |
| Physical features | Distinctive facial features are not established by the source. | Distinctive facial features are often reported. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 9 C4540171 when
Early motor disorder with suspected metabolic disease
The source links type 9 to brain development, movement, and childhood onset.
Moderate
Organic-acid abnormality without a chromosomal explanation
Metabolic testing may support aciduria, but a result is not itself a diagnosis.
Moderate
Severe neurodevelopmental course needing supportive care
Supplied severity is severe; individual prognosis remains unestablished.
Low
Choose 17p11 2 Microduplication Syndrome C2931246 when
Delay, learning difficulty, and facial differences
These features are described for 17p11.2 microduplication syndrome.
Moderate
Microarray identifies a 17p11.2 duplication
Chromosomal testing is central, but clinical correlation is required.
High
Moderate congenital presentation without metabolic markers
The supplied category is congenital and severity moderate.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 9 C4540171 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acids | May suggest 3-methylglutaconic acid elevation; cutoff not supplied. | Not expected to establish this syndrome. | An abnormal metabolite is a clue, not a standalone diagnosis. |
| Chromosomal microarray | Not described as the primary diagnostic test. | May detect duplication at 17p11.2. | A genetics clinician should interpret the finding in context. |
| Developmental assessment | Documents motor and cognitive effects. | Documents delay and learning needs. | Guides support but does not identify the cause. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 9 C4540171
- Outcome
- Described as severe, but individual outcome is not established.
- Factors
- Motor impairment, cognitive impact, and access to supportive care.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Often moderate developmental effects, with an unestablished range.
- Factors
- Learning needs, congenital features, and early developmental support.
Time frame: Childhood presentation with a chronic course; long-term data are not supplied.
Cause, severity, comorbidities, and services. Clinician interpretation is required.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopmental impairment | Cognitive and motor effects may be substantial. Learning and developmental challenges are commonly described. Severity varies and is not quantified here. |
| Educational support needs | Cognitive impact may require individualized support. Learning challenges often require educational planning. Specific deficits are not established by the source. |
| Diagnostic uncertainty | Metabolic abnormalities need confirmation and clinical correlation. A duplication finding needs phenotypic correlation. Neither test result alone proves the full diagnosis. |
Patient education highlights
- HighDifferent causes
One is a metabolic genetic disorder; the other is a chromosomal duplication. Neither is communicable.
- MediumTesting
Organic-acid and chromosomal tests answer different questions and require specialist interpretation.
- MediumCare
Care is individualized and supportive. No treatment dose or outcome can be inferred from these data.